JOURNAL OF THE CZECH PEDIATRIC SOCIETY AND THE SLOVAK PEDIATRIC SOCIETY

Čes-slov Pediat 2023, 78(6):330-334 | DOI: 10.55095/CSPediatrie2023/053

Renal involvement in pediatric inflammatory bowel diseaseComprehensive Report

Eva Švábová1, David Bauer2, Lucie Gonsorčíková2, Jakub Zieg1
1 Pediatrická klinika, 2. lékařská fakulta, Univerzita Karlova a FN Motol, Praha
2 Pediatrická klinika, 1. lékařská fakulta, Univerzita Karlova a Fakultní Thomayerova nemocnice

Incidence of inflammatory bowel diseases is rising worldwide, especially within the pediatric population. Except for bowel involvement, other organs may be affected in patients with inflammatory bowel disease. Extraintestinal manifestations usually involve joints, skin, bile ducts and eyes. However, another organ system which can be affected is the urinary tract, especially kidneys. The most commo

n renal manifestations of inflammatory bowel diseases are nephrolithiasis and renal parenchymal diseases, such as interstitial nephritis,

glomerulonephritis and amyloidosis. In this review, we focus on the spectrum of kidney involvement related to inflammatory bowel diseases.

Keywords: inflammatory bowel disease, extraintestinal manifestation, nephrolithiasis, interstitial nephritis, glomerulonephritis, amyloidosis

Accepted: October 23, 2023; Published: December 11, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Švábová E, Bauer D, Gonsorčíková L, Zieg J. Renal involvement in pediatric inflammatory bowel disease. Ces-slov Pediat. 2023;78(6):330-334. doi: 10.55095/CSPediatrie2023/053.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Béres NJ, Kiss Z, Sztupinszki Z, et al. Altered mucosal expression of microRNAs in pediatric patients with inflammatory bowel disease. Dig Liver Dis 2017; 49(4): 378-387. Go to original source... Go to PubMed...
    2. Benchimol EI, Fortinsky K J, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm. Bowel Dis 2011; 17(1): 423-439. Go to original source... Go to PubMed...
    3. Sýkora J, Pomahačová R. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol 2018; 24(25): 2741-2763. Go to original source... Go to PubMed...
    4. Mamula P, Markowitz JE. Inflammatory bowel disease in early childhood and adolescence: special consideration. Gastroenterol. Clin. North Am 2003; 32 (3): 967-95. Go to original source... Go to PubMed...
    5. Jang HJ, Kang B, Choe BH. The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults. Transl Pediatr 2019; 8 (1): 4. Go to original source... Go to PubMed...
    6. Ambruzs JM, Larsen CP. Renal manifestations of inflammatory bowel disease. Rheum Dis Clin North Am 2018; 44(4): 699-714. Go to original source... Go to PubMed...
    7. van Hoeve K, Hoffman I. Renal manifestations in inflammatory bowel disease: a systematic review. J Gastroenterol 2022; 57(9): 619-629. Go to original source... Go to PubMed...
    8. Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol 2014; 9(2): 265-270. Go to original source... Go to PubMed...
    9. Jang HM, Baek HS, Kim JE, et al. Renal involvement in children and adolescents with inflammatory bowel disease. Korean J Pediatr 2018; 61(10): 327-331. Go to original source... Go to PubMed...
    10. Mutalib M. Renal involvement in paediatric inflammatory bowel disease. Pediatr Nephrol 2021; 36(2): 279-285. Go to original source... Go to PubMed...
    11. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12(30): 4819. Go to original source... Go to PubMed...
    12. Ricart E, Sandborn WJ. Extraintestinal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis 2003: 257-277. Go to original source...
    13. Oikonomou K, Kapsoritakis A, Eleftheriadis T, et al. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 2011; 17(4): 1034-1045. Go to original source... Go to PubMed...
    14. Gkentzis A, Kimuli M, Cartledge J, et al. Urolithiasis in inflammatory bowel disease and bariatric surgery. World J Nephrol 2016; 5(6): 538. Go to original source... Go to PubMed...
    15. Stewart CS, Duncan SH, Cave DR. Oxalobacter formigenes and its role in oxalate metabolism in the human gut. FEMS Microbiol Lett 2004; 230(1): 1-7. Go to original source...
    16. Chandhoke PS. When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol 2002; 168(3): 937-940. Go to original source... Go to PubMed...
    17. Corica D, Romano C. Renal Involvement in Inflammatory Bowel Diseases. J Crohns Colitis 2015; 10(2): 226-235. Go to original source... Go to PubMed...
    18. Rehnberg J, Symreng A, Ludvigsson JF, Emilsson L. Inflammatory bowel disease is more common in patients with IgA nephropathy and predicts progression of ESKD: A Swedish population-based cohort study. J Am Soc Nephrol 2021; 32(2): 411-423. Go to original source... Go to PubMed...
    19. Takemura T, Okada M, Yagi K, et al. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications. Pediatr Nephrol 2002; 17(10): 863-866. Go to original source... Go to PubMed...
    20. Forshaw MJ, Guirguis O, Hennigan TW. IgA nephropathy in association with Crohn's disease. Int J Colorectal Dis 2005; 20(5): 463-465. Go to original source... Go to PubMed...
    21. Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomized, placebo-controlled phase 2b trial. Lancet 2017; 389(10084): 2117-2127. Go to original source... Go to PubMed...
    22. Velciov S, Gluhovschi G, Sporea I, et al. Asymptomatic urinary anomalies, hematuria and proteinuria, in patients with inflammatory bowel disease. Preliminary study. Rom J Intern Med 2001; 49(2): 113-20.
    23. Marcus SB, Brown JB. Tubulointerstitial nephritis: an extraintestinal manifestation of Crohn disease in children. J Pediatr Gastroenterol Nutr 2008; 46(3): 338-341. Go to original source... Go to PubMed...
    24. Waters AM, Zachos M, Herzenberg A, et al. Tubulointerstitial nephritis as an extraintestinal manifestation of Crohn's disease. Nat Clin Pract Nephrol 2008; 4(12): 693-697. Go to original source... Go to PubMed...
    25. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 2001; 7(4): 295-300. Go to original source... Go to PubMed...
    26. Tada Y, Ishihara S, Ito T, et al. Successful use of maintenance infliximab for nephropathy in a patient with secondary amyloidosis complicating Crohn's disease. Intern Med J 2013; 52(17): 1899-1902. Go to original source... Go to PubMed...
    27. Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008; 103(3): 776-787. Go to original source... Go to PubMed...
    28. Cucino C, Sonnenberg A. The comorbid occurrence of other diagnoses in patients with ulcerative colitis and Crohn's disease. Am J Gastroenterol 2001; 96(7): 2107-2112. Go to original source... Go to PubMed...
    29. Fernández-Nebro A, Ureña I, Irigoyen MV, García-Vicuña R. Anti-TNF-α for treatment of amyloidosis associated with Crohn's disease. Gut 2006; 55(11): 1666-1667.
    30. Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn's disease treated with infliximab. Inflamm Bowel Dis 2008; 14 (3): 431-432. Go to original source... Go to PubMed...
    31. Anelli MG, Torres DD, Manno C, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheumatol 2005; 52(8): 2519-2520. Go to original source... Go to PubMed...
    32. Boscá MM, Pérez-Baylach CM, Solis MA, et al. Secondary amyloidosis in Crohn's disease: treatment with tumor necrosis factor inhibitor. Gut 2006; 55(2): 294-295. Go to original source... Go to PubMed...
    33. Iizuka M, Konno S, Horie Y, et al. Watanabe S. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut 2006; 55(5): 744-745. Go to original source... Go to PubMed...
    34. Gisbert JP, González-Lama Y, Maté J. 5-aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13 (5): 629-38. Go to original source... Go to PubMed...
    35. Elseviers MM, D'Haens G, Lerebours E, et al. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin Nephrol 2004; 61: 83-9. Go to original source... Go to PubMed...
    36. Moss JG, Parry CM, Holt RC, McWilliam SJ. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review. Eur J Med Res 2022; 27(1): 61. Go to original source... Go to PubMed...
    37. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20(7): 1400-1406. Go to original source... Go to PubMed...
    38. Nielsen H, Kemp E, Petersen LJ, et al. Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. Arthritis Res Ther 2001; 3: 1. Go to original source...
    39. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007; 86(4): 242-251. Go to original source... Go to PubMed...
    40. Neale TJ, Rüger BM, Macaulay H, et al. Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 1995; 146: 1444-54.
    41. Ota M, Iwai H, Imai K, et al. Acute tubulointerstitial nephritis associated with infliximab in a patient with Crohn's disease. Intern Med 2016; 55: 1367-1370. Go to original source... Go to PubMed...
    42. Yoo YJ, Chung SY, Gu DH, et al. A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn's disease. Korean J Gastroenterol 2014; 63: 308-312. Go to original source... Go to PubMed...
    43. Subhaharan D, Ramaswamy PK, et al. Vedolizumab-induced acute interstitial nephritis in ulcerative colitis. ACG Case Rep J 2022; 9(6). Go to original source... Go to PubMed...
    44. Simpson N, Seenan JP, et al. Acute interstitial nephritis secondary to vedolizumab. BMJ Case Rep CP 2021; 14(11). Go to original source... Go to PubMed...
    45. Bailly E, Von Tokarski F, et al. Interstitial nephritis secondary to vedolizumab treatment in Crohn disease and safe rechallenge using steroids: a case report. Am J Kidney Dis 2018; 71(1): 142-145. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content